Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Docetaxel - Beihai Biotech

Next Previous
Drug Profile

Docetaxel - Beihai Biotech

Alternative Names: BH-009; BH-011; BH011 injection; Docetaxel injection

Latest Information Update: 19 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Beihai Biotech
  • Class Antineoplastics; Small molecules; Taxanes
  • Mechanism of Action Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Solid tumours
  • Phase I/II Bladder cancer

Most Recent Events

  • 30 May 2025 Updated adverse events and efficacy data from a phase I/II trial in Bladder cancer presented at 61st Annual Meeting of the American Society of Clinical Oncology
  • 22 May 2025 Safety, efficacy and pharmacokinetic data from a phase I trial in Bladder cancer presented at 61st Annual Meeting of the American Society of Clinical Oncology
  • 31 May 2024 Interim efficacy and adverse events data from a phase I trial in Solid tumors presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top